Navigation Links
Protein Markers for Identification of Brain Tumor

Professor Waldemar Debinski and his team from Wake Forest University Baptist Medical Center have found a new treatment for the brain tumor – glioblastoma multiforme. The scientists have found that the inactive form of EphA2 // protein in the brain cells were responsible for spread of cancer cells and the work was published in the Journal Molecular Cancer Research. Glioblastoma multiforme is the most common form of brain tumor and the least curable of all human cancers.

The Protein – EphA2:

Debinski has found a protein EphA2 in large amount in brain tumor patients compared to normal people, but they found that the protein in large amount was in an inactive form. EphA2 protein, which is found in cell membranes, allows normal cells to communicate with their environment and each other. In its normal active state, the protein seems to inhibit abnormal cell growth and division. Debinski found that the inactive form of EphA2 aids in the survival and spread of cancer cells.

Professor tested the treatment hypothesis by treating glioblastoma cells with ephrinA1, a naturally occurring molecule that binds to EphA2 and activates it. They had already demonstrated that ephrinA1 is present at much lower levels in cells and tumors with increased levels of inactive EphA2. The researchers found that cells treated with ephrinA1 slowed down their growth and were less likely to exhibit invasive properties. By changing the levels of EphA2 and ephrinA1 offers new promise for successfully treating glioblastoma multiforme.

Professor Debinski said, “We’ve found that a particular protein may play a major role in the progression of these tumors, suggesting an attractive new treatment approach and the EphA2 represents a novel target for the development of molecular therapeutics for the imaging and treatment of patients with glioblastoma,” Professor added that , “New therapies are clearly needed because, despite the standard treatment of surgically removing the tumor and treating the patient with chemotherapy and radiation, survival has increased only slightly over the past 30 years.”

Earlier Work of Debinski: Interleukin 13 –

Debinski had earlier found that cancer cells had a specific receptor for Interleukin 13 (IL-13), which is a naturally occurring protein that regulates the immune system in the body. Normal cells do not have these same receptors. Debinski developed a drug that combines a form of IL-13 with a toxin that kills cancer cells. By targeting the therapy to these receptors, the drug finds and kills the cancer cells. Debinski has been focusing on identification of new novel molecular markers, which helps in diagnosis of cancer in an early stage.

Source: Newwise.
'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
3. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of ‘Huntingtons’ Disase
4. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of Huntingtins’ Disese
5. Protein in urine foresees heart disease
6. Levels Of Blood Proteins May Help Heart Disease Care
7. Protein signals need for heart surgery
8. Protein and fat improve memory
9. Clotting Protein plays a role in nerve repair
10. High Levels of Protein Linked to Brain Shrinkage
11. Protein can change worn muscle fibres
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: